^
    Back
    Association details:
    Biomarker:HER-2 mutation + CDK6 mutation
    Cancer:Ampulla of Vater Carcinoma
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) +
    Perjeta (pertuzumab) (HER2 dimerization inhibitor) +
    Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) +
    Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) +
    Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Significance of scores generated by a cancer therapy matching engine for patient outcomes

    Published date:
    05/19/2021
    Excerpt:
    68-year-old female with an ampullary adenocarcinoma harboring ERBB2, CDK6 and other alterations, received a combination of pertuzumab and trastuzumab scoring 56%. The PFS was 745+ days. However, had palbociclib, ribociclib, or abemaciclib been added to this combination, the resulting 3-drug options would have scored even higher due to also targeting CDK6.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e15099
    Trial ID:
    I-PREDICT